BOSTON–(BUSINESS WIRE)–Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present eight studies, including two oral presentations, during the Digestive Disease Week® (DDW) 2022 meeting being held from May 21 through May 24, 2022 in San Diego, CA. One oral presentation will discuss the impact of novel guanylate cyclase-C agonist IW-3300 on comorbid chronic pelvic and somatic pain in a preclinical model of
Click here to view original post
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
